Full-Time

Area Associate Clinical Oncology Specialist

Posted on 1/24/2025

Natera

Natera

1,001-5,000 employees

Genetic testing and diagnostics solutions provider

Compensation Overview

$110k - $130kAnnually

Junior, Mid

Company Historically Provides H1B Sponsorship

United States

Position requires 75% travel within the northeast US region.

Category
Nursing & Allied Health Professionals
Medical, Clinical & Veterinary
Required Skills
Sales
Requirements
  • Bachelor’s degree or equivalent
  • Minimum of 2 years of sales experience or Clinical support/Caregiver experience such as OCN or other.
  • Background in medical or biological sciences is preferred
Responsibilities
  • Become product experts on all Natera Oncology products and processes to maximize effectiveness in the field.
  • Travel to temporarily vacant geographies within an Area/Region to ensure continuity of customer support and business pull through.
  • Increase unit volumes in existing accounts with a heavy emphasis in managing order renewals, Draw pull through, driving new patients with existing customers & closing new physicians within said account.
  • Take the lead in resolving Missing Information (MI) while partnering with assigned COS to achieve territory Missing Information (MI) goal, sell, maintain & support existing customers.
  • Focus on Pathology to assist in obtaining alternate pathology reports, expedite block shipment, stock kits, and provide top level customer service to our pathology partners.
  • Assess the needs of medical professionals and staff members with a focus on customer support, coordination of logistics, and problem solving.
  • Promote quality client/patient relations and create a supportive climate by serving as a role model for other employees.
  • Respect and maintain the confidentiality of laboratory and financial information.
  • Practice and adhere to all company policies and regulations.
  • Follow Compliance procedures and participates in Compliance training.
  • Perform miscellaneous duties with completion in a designated time frame.
  • Communicate with Natera staff and its customer to ensure quality.
Desired Qualifications
  • Proven track record of success in achieving and exceeding sales goals
  • Award winning sales professional due to individual achievements
  • Exceptionally bright, flexible, self-motivated, and results oriented with strong interpersonal and analytical skills
  • Ability to think strategically as well as execute tactically
  • Must act with a sense of urgency
  • Have a strong desire to work in a fast-pace environment and must work independently with an internal drive to be successful
  • Excellent organizational and communication skills (written and verbal) with demonstrated ability to effectively present to both internal and external customers
  • Effective time management skills required with a demonstrated ability to assess and prioritize
  • Proficient in Microsoft PowerPoint and Excel; Gmail; Sales Force.com

Natera focuses on genetic testing and diagnostics, utilizing cell-free DNA (cfDNA) testing to analyze DNA fragments in the blood for cancer detection and monitoring. Their services include the Signatera test for cancer patients, organ health assessments for transplant patients, and various tests for women's health, such as prenatal screening. Natera stands out by offering specialized testing solutions and genetic counseling services, which are often reimbursed by insurance. The company's goal is to provide advanced testing solutions that support patients and healthcare providers in making informed medical decisions.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Austin, Texas

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased adoption of liquid biopsy techniques boosts demand for Natera's cfDNA tests.
  • AI integration enhances accuracy of Natera's genetic tests, improving patient outcomes.
  • Telehealth expansion aligns with Natera's remote genetic counseling services, broadening their reach.

What critics are saying

  • Hindenburg's report accuses Natera of deceptive practices, risking legal and reputational issues.
  • CFO's stock sale may signal internal concerns about Natera's future performance.
  • Reliance on insurance reimbursements poses a risk if policies or rates change.

What makes Natera unique

  • Natera specializes in cell-free DNA testing for prenatal and cancer diagnostics.
  • The company offers the unique Signatera test for personalized cancer monitoring.
  • Natera's Prospera Heart test uses a novel Donor Quantity Score for transplant rejection detection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

9%
Financial Modeling Prep
Feb 28th, 2025
Lantheus Holdings, Inc. (NASDAQ:LNTH) Demonstrates Strong Capital Efficiency

Lantheus competes with other companies in the medical and pharmaceutical industries, such as ShockWave Medical, Medpace Holdings, LivaNova, Apellis Pharmaceuticals, and Natera.

BioSpace
Feb 19th, 2025
Natera To Report Its Fourth Quarter And Full Year Results On February 27, 2025

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2024, after the market closes on Feb. 27, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m

MarketBeat
Nov 24th, 2024
Alpha DNA Investment Management LLC Invests $505,000 in Natera, Inc. (NASDAQ:NTRA)

Alpha DNA Investment Management LLC invests $505,000 in Natera, Inc. (NASDAQ:NTRA).

MarketBeat
Sep 22nd, 2024
Delap Wealth Advisory LLC Makes New $454,000 Investment in Natera, Inc. (NASDAQ:NTRA)

Delap Wealth Advisory LLC makes new $454,000 Investment in Natera, Inc. (NASDAQ:NTRA).

Investing.com
Jul 2nd, 2024
Natera CFO sells over $539k in company stock

In other recent news, Natera Inc. has launched the DECIPHER trial for gastroesophageal adenocarcinoma (EGC) treatment, utilizing its molecular residual disease (MRD) test, Signatera.

INACTIVE